Skip to content
Business Times – Lifestyle
Author:
Skyhawk Therapeutics
Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington’s Disease to the United States, Canada and the United Kingdom
July 14, 2026
Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
June 30, 2026
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
June 1, 2026
/C O R R E C T I O N — Skyhawk Therapeutics/
May 18, 2026
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
May 18, 2026
Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society’s 2026 Medal of Honor
March 30, 2026